Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment exchanges : Amex save search
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.1877 -1.21% 0.0% 330K
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
NNVC | $1.1 -6.38% 0.0% 22K
|
Health Technology
|
| O: 2.56%
H: 0.83%
C: -0.83%
nv-387 covid report treatment trial
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
LCTX | $1.145 -4.58% 0.0% 1.1M
|
Health Technology
|
| O: 1.85%
H: 0.83%
C: -7.27%
fda cell treatment clearance
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -10.42%
patent treatment application
DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
Published: 2024-01-09 (Crawled : 13:00) - globenewswire.com
DXR | $9.74 0.73% 8.3K
|
Health Technology
|
| O: -0.98%
H: 0.75%
C: -0.1%
patent treatment blood smart technology
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
PHGE | News | $0.2852 -3.58% 0.0% 69K
|
Health Technology
|
| O: -0.37%
H: 6.26%
C: 0.04%
bx004 drug food infection treatment fibrosis designation
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
LCTX | $1.145 -4.58% 0.0% 1.1M
|
Health Technology
|
| O: 1.66%
H: 17.81%
C: 14.57%
drug treatment submission
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -4.92%
cancer pancreatic treatment namodenoson
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
PHGE | News | $0.2852 -3.58% 0.0% 69K
|
Health Technology
|
| O: -30.36%
H: 14.21%
C: -23.08%
bx004 positive treatment fibrosis topline infections trial results
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
Published: 2023-11-02 (Crawled : 13:00) - prnewswire.com
ATNM | $6.85 2.7% 0.0% 350K
|
Health Technology
|
| O: 1.29%
H: 3.83%
C: -16.58%
tp53 presentation treatment aml meeting trial
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
PHGE | News | $0.2852 -3.58% 0.0% 69K
|
Health Technology
|
| O: 11.07%
H: 0.0%
C: -8.33%
bx004 conference treatment ongoing fibrosis infections study
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Published: 2023-10-16 (Crawled : 20:00) - biospace.com/
PTN | $1.86 -1.59% 0.0% 150K
|
Health Technology
|
| O: 0.58%
H: 5.75%
C: 0.57%
pl8177 conference treatment week
Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
Published: 2023-10-13 (Crawled : 12:00) - globenewswire.com
DXR | $9.74 0.73% 8.3K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.11%
america treatment meeting heart technology
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
CVM | $1.545 3.0% 0.0% 230K
|
Health Technology
|
| O: 0.86%
H: 4.26%
C: -6.84%
multikine approval cancer treatment
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
PHGE | News | $0.2852 -3.58% 0.0% 69K
|
Health Technology
|
| O: 2.86%
H: 0.0%
C: -0.03%
bx004 treatment fibrosis infections study
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 5.79%
H: 1.82%
C: -8.76%
association cancer pancreatic treatment namodenoson research
Flow Diversion Aneurysm Treatment Market to grow by USD 2.11 billion from 2022 to 2027, North America to account for 38% of market growth - Technavio
Published: 2023-09-24 (Crawled : 04:20) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
| Email alert
Add to watchlist
TRUMY | $16.507 0.79% 34K
|
Manufacturing
| Email alert
Add to watchlist
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
| Email alert
Add to watchlist
NSPR 4 | $2.1409 -1.81% 16K
|
Health Technology
| Email alert
Add to watchlist
america treatment flow growth market
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Published: 2023-09-07 (Crawled : 22:00) - biospace.com/
PTN | $1.86 -1.59% 0.0% 150K
|
Health Technology
|
| O: 0.43%
H: 3.49%
C: -2.18%
pl9643 disease treatment eye study
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
PHGE | News | $0.2852 -3.58% 0.0% 69K
|
Health Technology
|
| O: -1.03%
H: 1.55%
C: 1.04%
bx004 treatment ongoing infections study
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.